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The Rho family of guanine 50-triphosphatases (GTPases) play
a key role in regulating cell proliferation, tubulointerstitial
fibrosis, and glomerular hemodynamics. The post-
translational prenylation of RhoGTPases by the addition of a
geranylgeranyl moiety is critical for cellular localization and
signaling activity. This study investigates the effects of (i)
inhibiting geranylgeranylation (GG) in human mesangial cell
(HMC) proliferation and apoptosis, using GGTI 298, a specific
inhibitor of GG and (ii) lovastatin, an HMG-coacetyl
A-reductase inhibitor, which depletes the availability of
prenylation substrates. HMC proliferation was assessed using
an assay of viable cell number and measuring
bromodeoxyuridine (BrdU) incorporation. Hoechst 33342
staining was used to determine apoptosis. Extracellular
signal-regulated protein kinase (Erk)1/2 and Akt activation
were analysed by Western blotting. Rho activation was
determined using the Rhotekin pull-down assay.
Immunocytochemistry was performed to study the effects on
the actin cytoskeleton and RhoA localization. GGTI 298
(10–20 lM) and lovastatin (5–10 lM) potently inhibited
platelet-derived growth factor and serum-stimulated HMC
proliferation and induced apoptosis. These effects of
lovastatin were attenuated by co-incubation with
geranylgeranylpyrophosphate. C3 exoenzyme, a clostridial
toxin that specifically targets Rho also inhibited BrdU
incorporation and promoted apoptosis. GGTI 298 increased
cytosolic expression of RhoA, prevented RhoA activation, and
inhibited the activation of Erk1/2 and the survival protein
Akt. GGTI 298, lovastatin, and C3 exoenzyme inhibit HMC
proliferation and promote apoptosis. Inhibiting GG increases
cytosolic RhoA expression, disrupts the actin cytoskeleton,
and inhibits RhoA activation. These results suggest that
targeting geranylgeranylated proteins with statins or GGTI
298 is a promising therapeutic strategy in human
mesangioproliferative renal disease.
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Aberrant human mesangial cell (HMC) proliferation plays an
important role in the pathogenesis and progression of
glomerular injury and glomerulosclerosis.1 HMC prolifera-
tion is a hallmark of both immune-mediated and non-
immune-mediated glomerular injury,2 and strategies to
inhibit MC proliferation have been shown to reduce
mesangial matrix production.3–5 Therefore, targeting key
signaling proteins that underlie HMC proliferation may lead
to the development of more effective therapies for mesan-
gioproliferative disease.
The intracellular signaling pathways of many mesangial
mitogens converge upon the Ras and Rho superfamily of
small monomeric guanine 50-triphosphatases (GTPases),6,7
which act as molecular switches, transducing extracellular
proliferative signals from the plasma membrane to the cell
nucleus. Work from our group has shown that targeting Ras
inhibits renal fibroblast proliferation in vitro8,9 and reduces
glomerular injury in the Thy 1.1 nephritis model of
mesangial proliferation.10 Rho GTPases play a key role in
regulating biological processes that require a coordinated
rearrangement of the actin cytoskeleton such as cell
contraction, cell migration, phagocytosis, and cytokinesis.11
In addition to their effects on the actin cytoskeleton,
Rho proteins also regulate a variety of other pathways
including gene transcription, cell proliferation, and cellular
transformation.11,12
Within the Rho superfamily of proteins, Rho itself
regulates the formation of stress fibers, whereas Rac has
been shown to induce lamellipodia and Cdc42 is involved in
the development of actin spikes or filopodia.13 Rho exists in
three main isoforms, namely RhoA, RhoB, and RhoC. The
functional differences between these isoforms remain poorly
understood. Once activated, Rho cycles from an inactive,
guanine diphosphate-bound form to an active, GTP-bound
form. GTP-bound Rho is then able to activate a number of
downstream effector cascades.14 Rho proteins are activated by
guanine nucleotide exchange factors and inactivated by
GTPase-activating proteins. Further regulation of Rho occurs
through guanine nucleotide dissociation inhibitors, which
sequester guanine diphosphate-bound Rho in the cytosol,
thereby inactivating them.11 Rho proteins undergo a series of
post-translational modifications to enable them to localize to
cellular membranes and function as signaling molecules.
Prenylation is a key modification that involves the binding of
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a hydrophobic, isoprenoid geranylgeranyl or farnesyl residue
to the cysteine (C) in the Rho carboxy-terminal CAAX motif
(where A is an aliphatic amino acid and X is methionine or
serine).15 RhoA and RhoC undergo geranylgeranylation
(GG), whereas RhoB can be either geranylgeranylated or
farnesylated.
There is an increasing body of evidence to demonstrate
that the antiproliferative effects of HMG-coacetyl A-reduc-
tase inhibitors (statins) are mediated by the depletion of the
prenylation substrate, geranylgeranyl pyrophosphate
(GGPP).16–18 Furthermore, simvastatin has been shown to
inhibit mesangial cell (MC) proliferation and matrix
expansion in an in vivo model of mesangial proliferative
nephritis.19 However, in addition to cell proliferation, factors
such as the release of profibrotic cytokines, influx of
inflammatory cells, and glomerular hemodynamics are
likely to be important in determining the response to
glomerular injury. Recent work using simvastatin in rat
MCs suggest that the antiproliferative effects of stains are
mediated through inhibiting the prenylation of Rho pro-
teins.20 In this study, we use lovastatin and GGTI 298 (a
specific geranylgeranyl transferase inhibitor) to study the role
GG plays in regulating HMC proliferation in primary culture
and the effect of GG on RhoA activation and downstream
signaling pathways.
RESULTS
HMC proliferation is dependent on geranylgeranylated
proteins
Figure 1a demonstrates that 10 mM lovastatin inhibited
serum-stimulated cell number curves after 72 h, causing a
reduction in cell number of 44% compared to vehicle-treated
cells. Lovastatin caused a similar reduction in cell number in
platelet-derived growth factor (PDGF)-stimulated HMCs as
shown in Figure 1b. The reduction in cell number was
attenuated by coincubation with the prenylation substrate,
GGPP. Specific inhibition of geranylgeranyl transferase with
GGTI 298 (20 mM) caused a reduction in cell number of 49%
at 72 h after serum stimulation as seen in Figure 1c. GGTI
298 (20 mM) also inhibited serum-stimulated bromodeoxyur-
idine (BrdU) incorporation by 89% after 24 h as seen in
Figure 1e. When HMC proliferation was stimulated by PDGF,
GGTI 298 reduced cell number by 59% at 48 h (as seen in
Figure 1d) and reduced BrdU incorporation by 79% when
compared to vehicle-treated cells (Figure 1f).
Inhibiting GG promotes HMC apoptosis
Lovastatin also had a proapoptotic effect in serum-
stimulated HMCs, with 13% of cells showing apoptotic
features after 48 h compared with control values of less than
2%. This effect was partially reversed after coincubation with
GGPP as shown in Figure 2a. GGTI 298 also induced
apoptosis in 24% of serum-stimulated HMCs (Figure 2b).
Figure 2c and d demonstrate that both lovastatin and GGTI
298 has similar proapoptotic effects in PDGF-stimulated
HMCs.
Targeting Rho with C3 transferase has antiproliferative and
proapoptotic effects in HMC
As Rho is a potential target of GG inhibitors, the effects of C3
transferase on HMC proliferation and apoptosis were
studied. C3 transferase is a clostridium botulinum toxin,
which specifically inactivates Rho through ADP-ribosylation
of asparginine 41. Figure 3 demonstrates that C3 transferase
(30 mg/ml) inhibited BrdU incorporation by 56% when
compared to vehicle-treated HMCs. C3 transferase also
induced apoptosis in 16% of HMCs as seen in Figure 3b.
Inhibiting GG disrupts the actin cytoskeleton
To investigate the hypothesis that RhoA is a target of GGTI
298, the effects of GGTI 298 on the actin cytoskeleton were
studied by staining actin with tetramethyl rhodamine
isothiocynate (TRITC)-conjugated phalloidin. As seen in
Figure 4, untreated, fetal calf serum (FCS)-stimulated cells
had marked stress fiber formation, whereas GGTI 298-treated
cells lost proper actin polymerization. C3 transferase also
caused a loss in stress fiber formation. Cells treated with
GGTI 298 also appeared to lose contact sites with surround-
ing cells.
RhoA is the predominantly expressed Rho isoform in HMC
Quantitative Western blotting was performed to assess the
relative expression of Rho isoforms in HMC using standard
recombinant Rho proteins and isoform-specific Rho anti-
bodies as shown in Figure 5. These results show that the
signal obtained with 40 mg of HMC lysate is equivalent to
approximately 15 ng of RhoA recombinant protein (upper
blot). Using an equal amount of cell lysate, the signal using
the RhoB antibody appears to be less than 2 ng of RhoB
recombinant protein (middle blot). Although the data using
the RhoC antibody is less clear, the signal for 40 mg of cell
lysate is less than 2 ng of RhoC recombinant protein RhoC
(lower blot). These results clearly show RhoA to be the
predominantly expressed Rho isoform in HMC.
GGTI 298 increases cytosolic expression of RhoA and
prevents RhoA activation
Immunocytochemistry was performed to assess the effects of
GG on the cellular localization of RhoA as shown in Figure
6a. As can be seen, in serum-starved cells RhoA appears to be
diffusely expressed throughout the cell, presumably owing to
sequestration of RhoA in the cytosol by Rho-GDI. However,
stimulation with serum caused most of RhoA to be
relocalized to perinuclear structures after 15 min. Pre-
treatment of cells with GGTI inhibits this translocation of
RhoA, with increased cytosolic staining of RhoA when
compared to serum-stimulated cells that had no prior
treatment with GGTI 298.
Figure 6b and c shows the effect of GGTI 298 on RhoA
activation using the Rhotekin pull-down assay for activated,
GTP-bound RhoA. There is little expression of active-RhoA
in serum-starved cells. Stimulation with serum increases the
activation of RhoA and this is partially inhibited by pre-
treatment with GGTI 298.
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Inhibiting GG attenuates activation of Erk1/2 and Akt
The effects of GGTI 298 on extracellular signal-
regulated protein kinase (Erk)1/2 and Akt activation
were studied. Figure 7 shows a representative Western blot
analysis of this experiment. As seen in the upper panel,
GGTI 298 partially inhibited serum-stimulated activation
of Erk1/2, without affecting expression of total Erk1/2.
GGTI 298 also partially inhibited the activation of the
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Figure 1 | Statin and GGTI actions on cell proliferation. (a, b) Inhibitory effect 10 mM lovastatin on serum- and PDGF-stimulated
HMC cell number curves. Co-incubation of lovastatin with GGPP abrogates this antiproliferative effect. Cell number was estimated using the
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay by measuring the 490 nM absorbance over
72 h. (c, d) Inhibitory effect of 10–20 mM GGTI 298 on serum- and PDGF-stimulated cell number curves. (e, f) Inhibitory effect of
10–20 mM GGTI 298 on serum- and PDGF-stimulated BrdU incorporation. The error bars are s.e.m., n¼ 3–6. ***Po0.001 with respect to
vehicle-treated cells.
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Figure 2 | Study of apoptosis. (a, c) Proapoptotic effects of 10 mM lovastatin and (b, d) 10–20mM GGTI 298 in serum- and
PDGF-stimulated HMCs. Apoptosis was determined by Hoechst 33342 and propidium iodide staining. Co-incubation of lovastatin with
7.5mM GGPP reduces the proapoptoic effects of lovastatin. The error bars are s.e.m., n¼ 3. *Po0.05 and ***Po0.001 with respect to
vehicle-treated cells.
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survival protein Akt by serum without affecting the
expression of total Akt.
DISCUSSION
We have shown that inhibiting GG with GGTI 298
and lovastatin in HMC inhibits cell proliferation and
induces apoptosis. Although these effects have been observed
in a number of cell types including smooth muscle cells21
and rat MCs,20 work in other cell models shows that
geranylgeranylated proteins (such as RhoB) may actually
inhibit cell proliferation.22,23 Similarly, the proapoptotic
effects of GGTI are not observed in all cell types, as in
human macrophages GGTI 298 actually protects the
cells from apoptosis.24 Taken together, these data suggest
that the effect of inhibiting GG needs to be determined in
individual cell types as the effects of geranylgeranylated
proteins on the cell cycle not only vary between cell types but
are also species-specific. Indeed, recent work from our lab has
shown key differences in GTPase biology between rodent
MCs and HMC.25
Although lovastatin also reduces the availability of both
GGPP and farnesyl pyrophosphate, we have recently shown
that inhibiting farnesylation with a potent, specific farnesyl-
transferase inhibitor had no effect on cell proliferation or
apoptosis.26 Thus, the antiproliferative and proapoptotic
effects of lovastatin appear to be specifically mediated by the
depletion of the isoprenyl substrate GGPP. Interestingly,
although studies in rat MCs also suggest that farnesylated
proteins do not regulate cell proliferation,16 in murine MCs
farnesyl substrates can ameliorate the antiproliferative effects
of lovastatin.27 Again, this suggests important species-specific
differences in the role of prenylated proteins in regulating cell
proliferation. The origins of such differences are unclear. Ras
GTPases in human and mouse MCs appear to play quite
distinct roles and, for example, Ha-Ras is antiapoptotic only
in mouse cells.27 Other differences may be explained by
different substrate availability in cells of different species.
GGTI 298 also inhibited the activation of phospho-Erk1/2
and phospho-Akt, but had no effect on Ras activation (data
not shown). This suggests that the effects of GGTI 298 on Erk
and Akt activation are directly owing to GG inhibition and
not simply a secondary consequence of the effects of GGTI
298 on cell proliferation and apoptosis. These signaling
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Figure 3 | Study of C3 transferase. (a) Inhibitory effect C3
transferase on BrdU incorporation in HMCs. HMCs were grown on
35 mm culture dishes until 70% confluent serum-starved for 24 h,
before treatment with 30mg/ml C3 transferase in 10% FCS. BrdU-
positive cells and the total number of normal nuclei were identified
as described in the Materials and methods section. Error bars are
s.e.m. More than 300 nuclei were counted from two independent
experiments. **Po0.01 with respect to vehicle-treated cells.
(b) Proapoptotic effect of 30 mg/ml C3 transferase in 10% FCS after
staining with Hoechst 33342 and propidium iodide as described
previously. Error bars are s.e.m. More than 300 nuclei were counted
from each of two independent experiments. **Po0.01 with respect
to vehicle-treated cells.
Vehicle GGTI 298 C3 transferase
Figure 4 | The cytoskeleton. TRITC-phalloidin staining of the actin
cytoskeleton. HMCs were grown on coverslips in 10% FCS and either
left (a) untreated, (b) treated with 20mM GGTI 298, or (c) 30mg/ml C3
transferase for 24 h. Cells were fixed with 4% paraformaldehyde and
stained with TRITC-phalloidin (1:500) for 30 min. Images were viewed
with a confocal microscope at original magnification  400.
 Cell lysate Recombinant RhoA
2 ng 5 ng 10 ng 15 ng 20 ng
 Cell lysate Recombinant RhoB
2 ng 5 ng 10 ng 15 ng 20 ng
 Cell lysate Recombinant RhoC
2 ng 5 ng 10 ng 15 ng 20 ng
Ab: RhoA 
Ab: RhoB 
Ab: RhoC
Figure 5 | Quantitative Western blot analysis of HMC lysate for
Rho isoforms. These are compared to recombinant Rho proteins
(2–20 ng) when detected with isoform-specific antibodies. The upper
panel was detected with the anti-RhoA antibody, the middle panel
was detected with the anti-RhoB antibody, and the lower panel was
detected with the anti-RhoC antibody. These figures were represen-
tative of three separate experiments.
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effects of GGTI 298 are likely to be the result of inhibiting a
range of geranylgeranylated proteins, including Rho, Rac, and
Cdc42. This hypothesis is supported by the observation that
both C3 transferase and GGTI 298 reduced HMC prolifera-
tion, increased apoptosis, and inhibited stress fiber forma-
tion. As C3 transferase specifically inactivates the Rho
isoforms and has no effect on Rac and Cdc42 activation, it
is likely that some of the effects of GGTI 298 on cell-cycle
progression and stress fiber formation are mediated by
targeting of Rho isoforms. Furthermore, treatment with
GGTI 298 is associated with altered RhoA distribution and
activation. Taken together, these data strongly implicate
RhoA as being a key target of GGTI 298.
The roles of RhoB and RhoC are harder to define.
Quantitative Western blotting suggests that both RhoB and
RhoC protein expression is less than 5% of total Rho
expression in HMC. RhoB appears to actually inhibit cell
proliferation and can be farnesylated,22 and therefore it is
unlikely to be a target through which GGTI 298 mediates its
antiproliferative effects. We are currently clarifying the role of
RhoC using specific small interfering RNA. Owing to the
minimal expression of RhoC in HMC and the relative
insensitivity of the RhoC antibody, we were unable to
ascertain the effect of GG inhibition on RhoC activation.
However, its role in cell proliferation may be very important
as there is evidence linking RhoC to malignant transforma-
tion and metastasis.28 At present, little is known about precise
biological roles of the Rho isoforms in HMC. Preliminary
unpublished work in our lab using small interfering RNA
targeting each isoforms suggests that both RhoA and RhoC
are important in regulating MC proliferation.
The mechanism by which Rho regulates cell proliferation
is likely to involve a number of different pathways, including
the regulation of key cell-cycle regulatory proteins such
as cyclins and cyclin-dependent kinase inhibitors. For
example, targeting Rho (using either GGTI 298, statins,
or C3 transferase) results in increased expression of the
cyclin-dependent kinase inhibitors, p21(WAF1) and p27 KIP1,
thereby inhibiting cell-cycle progression.29–31 RhoA can also
activate transcription factors such as serum response factor.13
Furthermore, RhoA appears to be required for sustained
growth factor activation of the Ras–Raf—MAP kinase
kinase–Erk pathway.32 This observation is consistent with
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Figure 6 | RhoA activity. (a) Effect of GGTI 298 on RhoA localization.
HMCs were plated on to coverslips and serum-starved for 24 h. They
were then left in serum-free medium overnight with or without GGTI
298 20 mM. They were then fixed or stimulated with 10% FCS for
10 min as indicated followed by fixation. RhoA was detected with a
specific anti-RhoA antibody and a fluorescein isothiocyanate-labeled
secondary antibody. The cells were viewed at  200 original
magnification with a fluorescent microscope. (b) Inhibitory effect of
GGTI 298 on RhoA activation. HMCs were grown to 90% confluence,
then serum starved for 24 h, incubated with either 20 mM GGTI 298,
vehicle alone, or serum-free media for a further 24 h. Untreated,
serum-starved cells were then lysed, whereas vehicle- and GGTI 298-
treated cells were stimulated with 10% FCS for 10 min before lysis.
GTP-bound Rho was immediately recovered as described in the
Materials and methods and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blotting. The top
panel shows a Western blot for GTP-bound Rho, whereas the bottom
panel shows a Western blot for total cellular Rho taken from the same
cell lysates. Data shown are representative of two separate
experiments. (c) Effects of 20 mM GGTI 298 on RhoA activation as
determined by densitometric analysis.
Phospho-Erk1/2
Total Erk1/2 
10% FCS −        +     + 
GGTI 298 −        −     +
Phospho-Akt
Total Akt
Figure 7 | Western blots for phospho-(Erk 1/2) and phospho-Akt
activation in stimulated HMC after overnight treatment with
GGTI 298 20 lM and stimulation with 10% FCS for 5 min were
shown. As can be seen, GGTI 298 20 mM inhibits the phosphorylation
of both Erk1/2 and Akt by serum. Total Erk1/2 and Akt remained
unchanged. Blots shown are representative of two separate
experiments.
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our data showing that GGTI 298 clearly inhibits Erk
activation, suggesting that Rho has a permissive effect on
the activation of the Ras-mediated cell proliferation. As both
C3 and GGTI 298 promoted disruption of the actin
cytoskeleton, it is also possible that an intact actin
cytoskeleton is a pre-requisite for effective for growth-
factor-stimulated cell proliferation and Erk signaling. Rho
could also directly activate Erk, although the mechanism by
which such activation could take place has not been
elucidated.
It is important to note that a number of other
geranylgeranylated proteins may mediate the effects of GGTI
in HMC, including Rac, Cdc42, and Rap. For example,
dominant-negative forms of Rac and Cdc42 have been shown
to inhibit DNA synthesis in fibroblasts.12 These effects may be
mediated through the regulation of transcription factors such
as serum response factor and nuclear factor-kappa B, as well
as the activation of other mitogen-activated protein kinase
cascades such as the p38 and janus kinase signaling
pathways.14 Rac and cdc42 may also regulate cell proliferation
by modulating Erk activity. For example, constitutively
activated Rac and cdc42 have been shown to increase Erk
activation.33 Furthermore, Rac appears to exert a permissive
effect on Ras-dependent Erk activation via the serine/
threonine kinase PAK.33 Rac may also promote cell
proliferation by targeting cell-cycle regulatory proteins. For
example, activated Rac has been shown to increase cyclin D
expression, thereby promoting cell proliferation.14
The effects of Rap on the cell cycle are complex. There is
evidence to suggest that Rap can antagonize Ras-stimulated
cell proliferation, whereas in other cell types, Rap promotes
mitogen-activated protein kinase activation.34
The effects of geranylgeranylated proteins on the actin
cytoskeleton have been defined for some time. Microinjection
studies using constitutively activated mutants demonstrated
that Rho was able to induce the assembly of contractile actin
and myosin filaments (stress fibers).35 Rac was shown to
induce actin-rich curtain-like extensions (lamellipodia or
ruffles) often formed along the edges of cells,36 whereas
Cdc42 induced the formation of filopodia (actin-rich, finger-
like membrane extensions) that probably regulate recognition
of the extracellular environment.13 Thus, these proteins
regulate three separate signal-transduction pathways that link
plasma membrane receptors to the assembly of distinct actin
structures.11 There has been little work looking at the specific
role of Rac and Cdc42 in HMC. However, connective tissue
growth-factor-induced migration of MCs appears to be in
part mediated by Cdc42.37
Immunocytochemistry for RhoA revealed some surprising
results, suggesting that in HMC, RhoA may signal from
intracellular compartments and not from the plasma
membrane. There are very little data using immunocyto-
chemistry to study endogenous RhoA localization. Some data
suggest that RhoA may be activated at the plasma
membrane,38,39 whereas others have shown little evidence
for RhoA localizing to the plasma membrane.40 Thus, GG
may serve to localize RhoA to specific compartments within
the cell. Recent work has shown that Ras can signal from the
Golgi complex and not only from the plasma membrane as
previously thought, suggesting that in certain cell types, Ras
and Rho GTPases may signal from intracellular compart-
ments.41
Our data show that geranylgeranylated proteins promote
cell survival through the activation of the phosphatidylino-
sitol 30-kinase/Akt signaling pathway. Recent work in human
cancer epithelial cells demonstrates that GGTI may promote
apoptosis by inhibiting the activation of Akt.42 It is not clear
which geranylgeranylated protein activates Akt, but both Rac
and Cdc42 can interact specifically with phosphatidylinositol
30-kinase and activate Akt.43 Furthermore, Rac appears to
play a key role in transducing integrin-mediated survival
signals.44 RhoA may also protect against apoptosis by
upregulating the expression of the survival protein Bcl-221
or increasing the expression of the tumor suppressor protein,
p53.45 Although MC apoptosis may have a valuable role in
counterbalancing excessive MC proliferation in vivo,46 other
work suggests that apoptosis may be harmful by promoting
glomerular hypocellularity.47 MC proliferation may be seen
in some situations as a reparative response to glomerular
injury (e.g. post-streptococcal GN) and thus inhibiting
repopulation of the glomerulus may prevent effective
glomerular remodeling and repair. Therefore, inhibiting
MC proliferation and promoting apoptosis per se may be a
double-edged sword depending on the specific clinical
context.
Rho plays a key role in regulating three distinct biological
processes that are critical to the progression of many renal
diseases, namely (i) cell proliferation and migration, (ii)
tubulointerstitial fibrosis, and (iii) glomerular hemody-
namics.48 Therefore, targeting Rho signaling could be a
particularly attractive therapeutic strategy. The use of statins
to target Rho and inhibit MC proliferation may be of
therapeutic value. Clinical trials of statins in mesangiopro-
liferative disease are required to determine whether they will
be an effective therapeutic in the future. Future strategies to
target RhoA signaling include the use of Rho kinase (ROCK)
inhibitors. These have been shown to attenuate cell
proliferation, fibrosis and macrophage infiltration in sub-
totally-nephrectomized spontaneously hypertensive rats.49
Furthermore, these inhibitors promote vascular smooth
muscle cell relaxation by increasing myosin light chain
phosphatase activity and appear to have beneficial effects on
the renal microcirculation.50,51 ROCK inhibitors are currently
in clinical trials for the treatment of cerebral vasospasm, but
their beneficial effects in a variety of models of renal injury
suggest they may be a promising development in the
treatment of progressive renal diseases.48
Taken together, this work indicates that inhibiting Rho
with either statins or GGTI may have beneficial effects in
progressive renal diseases. Although statins are widely used
clinically, GGTI have not yet been developed as a therapeutic
because of worries about toxicity. However, GGTI 298 has
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been given in a rat model of malignant glioma without
evidence of in vivo toxicity,52 suggesting that specific
targeting of geranylgeranylated proteins may be an alternative
clinical strategy in proliferative renal diseases.
MATERALS AND METHODS
Materials
All reagents and antibodies were purchased from Sigma-
Aldrich (Gillingham, UK), unless otherwise stated. GGTI 298
was a kind gift from SM Sebti, University of Florida. Vehicle
for GGTI 298 was 0.2% dimethylsulfoxide. We have recently
shown that GGTI 298 inhibits the prenylation of Rap1a, an
exclusively geranylgeranylated protein.26 Vehicle for lovasta-
tin (Calbiochem, UK) was ethanol 25 mg/ml. RhoA, RhoB,
and RhoC standard recombinant proteins were a kind gift
from Shawn Ellerbroek, Department of Cell and Develop-
mental Biology, University of North Carolina. Antibodies
used were anti-Phospho-Erk1/2 and anti-phospho-Akt (Ser
473) antibodies (New England Biolabs, Hitchin, UK), anti-
RhoA (sc-418), anti-RhoB (sc-8048) and anti-RhoC (sc-
12116) antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Dot blots were
performed using RhoA, RhoB, and RhoC standard recombi-
nant proteins and isoform-specific Rho antibodies. We and
other workers53 have demonstrated that these isoform-
specific antibodies were used at concentrations at which they
did not crossreact with other Rho isoforms (data not shown).
Primary HMC culture
Primary culture HMC (Clonetics Biowhittaker, Wokingham,
UK) were maintained in Rosewell Park Memorial Institute
1640 (Invitrogen Limited, Inchinnan, UK) medium with 10%
FCS. All experiments were carried out between passages 6
and 9.
Cell proliferation
To study the effects of GGTI 298 and lovastatin on
proliferation, HMCs were serum starved for 24 h, trypsinized,
and seeded in triplicate into 96-well plates (5000 cells/well).
GGTI 298 (0–20 mM), lovastatin (10 mM), and lovasta-
tinþGGPP (7.5 mM) were added and cells were grown in
10% FCS or PDGF (200 ng/ml). Viable cell numbers were
determined by the Cell titer 96, Promega assay (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium) measuring absorbance at 490 nm.
The correlation between viable cell number and absorbance
at 490 nm is linear.
DNA synthesis was assessed by BrdU uptake. Cells were
grown in 35 mm dishes and serum starved for 24 h before
treatment with GGTI 298, lovastatin, or C3 transferase in the
presence of 10% FCS. Six hours after the addition of drug
and growth factor, BrdU (10 mM) was added to each dish for
16 h. Dishes were then washed with phosphate-buffered
saline (PBS) and fixed for 45 min (three volume 50 mM
glycine and seven volume ethanol). Cells were then incubated
in 4 M hydrochloric acid for 10 min, washed three times in
PBS, and blocked in 5% goat serum/0.05% Tween/PBS for
15 min before being incubated overnight in anti-BrdU
antibody (1 in 100 dilution) at 41C. Cells were washed with
PBS and incubated for 30 min with TRITC-labeled antimouse
immunoglobulinG antibody. Cell nuclei were then counter-
stained with Hoechst 33342 at a concentration of 5 mg/ml for
15 min. Cells were then visualized with a fluorescent
microscope. BrdU-positive cells stain nuclei red, whereas all
cell nuclei would stain blue with Hoechst 33342. A total of at
least 150 cells were counted from at least five different fields.
Nuclei that appeared apoptotic on Hoechst 33342 staining
were not counted.
Apoptosis
HMCs were grown in serum in 35 mm dishes and treated
with GGTI 298 or lovastatin as before. Hoechst 33342 was
added (5 mg/ml) and then incubated at 371C for 15 min
followed by propidium iodide (5 mM) for 5 min. Cell nuclei
were then visualized under fluorescent microscopy. Apoptotic
nuclei were then identified as showing characteristic signs of
chromatin condensation and fragmentation. Late apoptotic
or necrotic cells stained red. A total of at least 150 cells were
counted from at least five different fields.
Immunocytochemistry and actin staining
Cells were grown on glass coverslips in 35 mm tissue culture
dishes. Cells were seeded in normal growth medium and left
for 24 h. The growth medium was then removed and the cells
were left overnight either in serum-free medium alone or
serum-free medium in the presence of GGTI 298. The
medium was removed the next day and the cells were treated
with 10% FCS for 10 min or left in serum-free medium. The
coverslips were washed three times in PBS and then fixed in
4% paraformaldehyde for 10 min. Cells were washed again,
permeabilized with 0.2% Triton X-100/PBS, and blocked
with 5% goat serum/PBS. Coverslips were incubated with an
anti-RhoA antibody at 41C overnight, washed three times in
PBS before incubation with a fluorescein isothiocyanate-
conjugated secondary antibody for 30 min at room tempera-
ture. The coverslips were again washed three times in PBS
and mounted onto glass slides with slow-fade mounting
medium (Molecular Probes, Eugene, OR, USA; S7461). Cell
staining for RhoA was then visualized by conventional
fluorescent microscopy. To stain for the actin cytoskeleton,
cells were fixed, permeabilized, and blocked as above before
incubation with TRITC-conjugated phalloidin (1:500) for
30 min at room temperature. Coverslips were then washed
and mounted, before viewing with the confocal microscope.
Western blotting
For Western blotting experiments, HMCs were grown to 80%
confluence in 35- or 100-mm plates, in Rosewell Park
Memorial Institute 1640 and 10% FCS. Cells were then
serum-starved for 24 h and then treated for a further 24 h
with 20 mM GGTI 298 in serum-free media containing either
10% FCS. Cells were stimulated for 5 min with 10% FCS, cell
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lysates were extracted on ice, denatured in Western sample
buffer, and 2-mercaptoethanol for 5 min at 1001C, before
performing sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and Western blotting. Protein expression was
detected by Amersham ECL chemiluminescence (Amersham
Pharmacia Biotech, Little Chalfont, UK).
Rho activation
Affinity precipitation using the Rho-binding domain of
Rhotekin (a downstream effector of Rho) was used to
determine Rho activation. Nuclear material was removed by
centrifugation and lysates were immediately precipitated with
60 ml of a 50% slurry of the Rhotekin–Rho-binding
domain–glutathione-S-transferase–agarose, rotating at 41C
for 45 min, to pull-down activated, GTP-bound Rho. The
samples were then pelleted at 14 000 g at 41C for 2 min and
washed twice in magnesium lysis buffer and denatured in
Western sample buffer as before, before sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunoblot-
ting using an anti-RhoA antibody.
Statistical analysis
Statistical analysis was performed using analysis of variance
followed by Dunnetts test of significance or an unpaired t-test
using Prism software.
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